Jiangsu Zenji

Jiangsu Zenji Biopharmaceutical is a China-based biotechnology company focused on the development and commercialization of innovative biopharmaceuticals, particularly in the fields of oncology and immunology. The company specializes in recombinant protein drugs and monoclonal antibodies, with a notable focus on cytokine therapies such as modified Interleukin-2 (IL-2) variants designed to improve safety and efficacy in treating solid tumors. Jiangsu Zenji operates integrated research, development, and manufacturing facilities to support its pipeline from early-stage discovery through clinical trials. Their lead programs aim to address significant unmet needs in cancer immunotherapy and inflammatory conditions.